Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Active not recruiting 2

Sponsor Class

INDUSTRY 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Ovarian Neoplasms 24Fallopian Tube Neoplasms 20Breast Neoplasms 10Carcinoma, Ovarian Epithelial 8Sarcoma 6Neoplasms 4Neoplasm Metastasis 4Triple Negative Breast Neoplasms 3Sarcoma, Kaposi 2Sarcoma, Ewing 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Multi-centric Castleman's Disease 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Leiomyosarcoma 2Hodgkin Disease 2Burkitt Lymphoma 2Acquired Immunodeficiency Syndrome 2AIDS-related Kaposi sarcoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Vaccinia 1Uterine Cervical Neoplasms 1Sarcoma, Synovial 1Rhabdomyosarcoma 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma 1Recurrence 1Peritoneal Neoplasms 1Pancreatic Neoplasms 1

Interventions

pembrolizumab 104Specimen Handling 55Magnetic Resonance Spectroscopy 48Biopsy 46Nivolumab 41Paclitaxel 35Gemcitabine 30Radiosurgery 29Carboplatin 28Ipilimumab 22Cyclophosphamide 22Cisplatin 22trastuzumab deruxtecan 21Irinotecan 21Capecitabine 19Leucovorin 18Fulvestrant 18Cetuximab 18130-nm albumin-bound paclitaxel 18Pemetrexed 17Fluorouracil 17Docetaxel 17Bevacizumab 17Drug Therapy 16Taxes 15Oxaliplatin 15olaparib 14abemaciclib 14Radiotherapy 14Trastuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Neoplasm Metastasis × liposomal doxorubicin × 1 year × Clear all
NCT07213804 2026-05-27

FRAmework-01

Eli Lilly and Company

Phase 3 Recruiting
1,080 enrolled
Gynecologic

Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Peritoneal Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT04895358 2026-03-11

KEYNOTE-B49

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
340 enrolled
Breast

Parkinson Disease 4, Autosomal Dominant Lewy Body, Breast Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡